AXSM News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AX

Mkt Cap

$8.23B

Volume

535.92K

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

2 Under-the-Radar Stocks to Buy and HoldThe article recommends two underrated biotech stocks: Axsome Therapeutics, which is experiencing strong growth with its drug Auvelity (51% YoY sales growth) and has a promising pipeline including potential new indications; and Exelixis, a cancer-focused biotech with a dominant drug Cabometyx protected until at least 2030, plus encouraging progress on pipeline candidates like zanzalintinib.The Motley Fool · Oct 16, 2026

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene.Zacks Investment Research · Oct 13, 2026

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?Axsome Therapeutics' Auvelity drug is expanding beyond major depressive disorder into Alzheimer's agitation treatment, with Q2 sales reaching $180.3 million (up 51% YoY) and new patient starts among seniors jumping 126% post-launch. The company projects Auvelity could eventually generate $8 billion in annual peak sales, with additional commercial products and pipeline candidates potentially transforming Axsome into a major neuroscience pharmaceutical company by 2030.The Motley Fool · Oct 12, 2026

4 CNS Drug Stocks Worth Watching This World Mental Health DayFour central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders.Zacks Investment Research · Oct 9, 2026

Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?Axsome Therapeutics reported Q2 2026 earnings that met EPS estimates but missed revenue expectations at $218.4M vs. $225M consensus. While lead drug Auvelity drove strong 51% YoY sales growth to $180.3M and Sunosi performed well, newest drug Symbravo significantly underperformed at $2.3M against $7.2M estimates. Post-earnings, analyst estimates have trended downward, and the stock has underperformed the S&P 500 by 3.7% over the past month.Zacks Investment Research · Sep 9, 2026

PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the CompanyPVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.GlobeNewswire Inc. · Sep 3, 2026

Axsome Begins Phase III Study on AXS-05 for Smoking CessationAxsome Therapeutics has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for smoking cessation. The randomized, double-blind, placebo-controlled trial will compare AXS-05 against bupropion and placebo over 12 weeks, with smoking abstinence as the primary endpoint. Axsome's lead drug Auvelity continues to drive strong revenue growth, generating $333 million in H1 2026 (up 54.2% YoY), while the company's diversified portfolio includes Sunosi and newly launched Symbravo.Zacks Investment Research · Sep 1, 2026

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10Axsome Therapeutics announced it will report Q2 2026 financial results on August 10, 2026, followed by a management conference call at 8:00 a.m. ET. The company is advancing its CNS disorder treatment portfolio with FDA-approved products including SUNOSI, AUVELITY, and SYMBRAVO, while progressing multiple clinical trials including Phase 3 FOCUS-2 and FOCUS-3 trials for solriamfetol in pediatric and adolescent ADHD patients.GlobeNewswire Inc. · Jul 14, 2026

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even MoreThree biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb another 13% due to recent drug approvals and strong pipeline progress.The Motley Fool · Jul 6, 2026

Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.Axsome Therapeutics has experienced significant growth with its CNS disorder treatments, including recently approved drugs Auvelity for Alzheimer's agitation and Symbravo for migraines. While the stock has climbed 220% over three years and has strong revenue growth, the article cautions that reaching millionaire status from a single stock investment is unrealistic, recommending instead a diversified portfolio approach.The Motley Fool · Jul 2, 2026

AX

AXSMAxsome Therapeutics, Inc

AXSM

Pay with—

Available Balance0.00

Your PositionYou don't own any AXSM yet.

Related Tickers

Earnings